Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FTC lice Internet surf

This article was originally published in The Tan Sheet

Executive Summary

Twenty-eight Web sites advertising lice treatment products were identified during a surf conducted by FTC's Division of Enforcement and Western Regional Office, the commission announces April 11. Many claims, such as "100% effective in killing lice and their eggs" and "eliminate the need for combing," may be misleading, FTC notes. While no enforcement actions have been taken, the agency has sent letters to the companies reminding them claims need adequate substantiation. The surf follows up on settlements FTC reached with Del Pharmaceuticals, Pfizer and Care Technologies regarding allegedly deceptive advertising claims made for their pediculicides (1"The Tan Sheet" Jan. 4, 1999, In Brief)

You may also be interested in...



FTC orders with Del, Pfizer, Care Technologies

Give final approval to separate consent orders regarding Del's Pronto shampoo, Pfizer's RID shampoo and egg removal comb and Care Technologies' Clear shampoo and lice egg remover to settle allegations the companies made false and unsubstantiated claims for the OTC head lice treatments. Proposed in September, the orders require that for two years, whenever a claim is made regarding product efficacy, the marketers include a disclosure about the necessity of a second treatment application ("The Tan Sheet" Sept. 28, 1998, p. 22). While the commission vote to make the orders final was unanimous, Commissioner Orson Swindle reiterated his concern about the disclosure requirement. The order against Del also prohibits claims about the extent to which health care professionals recommend Baby Orajel

People In Brief

Perrigo promotes in pricing, planning

In Brief

Combe sells most of its OTC brands

Topics

UsernamePublicRestriction

Register

PS091095

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel